Press Releases
2008 | 2007 | 2006 | 2005
Zelos Therapeutics to Present at Two Investor Conferences
West Conshohocken, PA, October 23, 2008 - Dr. Brian MacDonald, Chief Executive Officer of Zelos Therapeutics, Inc., will present at the following two investor conferences:
- The 7th Annual BIO Investor Forum being held from October 29-31, 2008 at the Palace Hotel in San Francisco, CA. Dr. MacDonald will present a corporate overview on Thursday, October 30, 2008 at 2:15 PM (PT) in the Pacific Heights Room.
Dr. MacDonald will also participate in a Therapeutic Workshop at the BIO Investor Forum entitled, “Opportunity in Osteoporosis and Bone Metabolism Disorders is Spurring Pipeline Growth,” which is being held on Thursday, October 30, 2008 from 5:00 PM - 6:15 PM (PT) in the Sea Cliff Room.
- Rodman & Renshaw 10th Annual Healthcare Conference being held from November 10-12, 2008 at the New York Palace Hotel in New York, NY. Dr. MacDonald will present a corporate overview on Monday, November 10, 2008 at 9:55 AM (ET) in the Louis Room.
About Osteoporosis
Osteoporosis is a disease in which bones become fragile and are more likely to break. If not prevented or if left untreated, osteoporosis can progress painlessly until a bone breaks or fractures, typically in the hip, spine, and wrist. Osteoporosis is a leading cause of morbidity and mortality in elderly people worldwide. The World Health Organization classifies osteoporosis as second only to cardiovascular disease in the severity of its effects. In the U.S. alone, more than 44 million men and women have osteoporosis, or low bone-mineral density. Thirty percent of women and 10 percent of men in the U.S. will develop osteoporosis during their lifetime.
About ZT-031
ZT-031 (formerly Ostabolin-C™) is a proprietary cyclic 31-amino acid parathyroid hormone (PTH) analog being developed for the treatment of osteoporosis. ZT-031 was recently studied in a 12-month double-blind, placebo-controlled Phase 2 study in 261 postmenopausal women with low bone mass (osteoporosis) at either the hip or the lumbar spine. In this study, ZT-031 was shown to be a bone formation agent with a rapid onset of effect leading to clinically relevant increases in bone mineral density (BMD) with no adverse events due to hypercalcemia observed.
Zelos Therapeutics recently reached agreements with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) for the design, conduct and analysis of a pivotal Phase 3 clinical study of ZT‑031 for the treatment of severe osteoporosis. The trial, if successful, would form the primary basis for an efficacy claim to support applications for marketing authorization of ZT-031 in the United States and Europe.
Zelos Therapeutics is also evaluating potential orthopedic uses of ZT-031’s bone formation properties for fracture repair, trauma and use as a surgical adjunct.
About Zelos Therapeutics, Inc.
Zelos Therapeutics specializes in the development of innovative treatments for bone disorders and related indications in large, underserved markets. Led by an experienced team of biopharmaceutical executives and funded by leading health care investors, Zelos Therapeutics is advancing a portfolio of product opportunities into late-stage clinical trials. For more information about Zelos Therapeutics, please visit the Company’s website at www.zelostherapeutics.com.
Investor Contact
Alan Roemer
Chief Financial Officer
Zelos Therapeutics, Inc.
(610) 825-1468
aroemer@zelostherapeutics.com
